Lithium Hydroxide → HCID 59497611、化合物
反応式
C[O:2][C:3](=[O:28])[CH2:4][CH2:5][N:6]1[C:10]2[CH:11]=[CH:12][CH:13]=[CH:14][C:9]=2[N:8]([CH2:15][C:16]2[CH:24]=[C:23]([Cl:25])[CH:22]=[C:21]3[C:17]=2[CH2:18][C:19](=[O:26])[NH:20]3)[C:7]1=[O:27].[OH-].[Li+]>O.O1CCOCC1>[Cl:25][C:23]1[CH:22]=[C:21]2[C:17]([CH2:18][C:19](=[O:26])[NH:20]2)=[C:16]([CH2:15][N:8]2[C:9]3[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=3[N:6]([CH2:5][CH2:4][C:3]([OH:28])=[O:2])[C:7]2=[O:27])[CH:24]=1参加物
4
実験手順
3-[3-(6-Chloro-2-oxo-2,3-dihydro-1H-indol-4-ylmethyl)-2-oxo-2,3-dihydro-benzoimidazol-1-yl]-propionic acid methyl ester (34 mg 0.09 mmol) is dissolved in dioxane water (2 mL/2 mL) and lithium hydroxide (18 mg, 0.45 mmol) is added in one portion. The reaction is stirred for one hour then the solvents evaporated in vacuo. The crude material is purified by preparative reverse phase LC to give the title compound (12 mg 0.03 mmol, 36%). LCMS (ESMS): m/z 387.1 (M+H+).
後処理
- customthe solvents evaporated in vacuo
- customThe crude material is purified by preparative reverse phase LC
出典と根拠
- ORDレコード
- ord-f9ed6f589a7f408b99d44975ba774f83
- 出典データセット
- uspto-grants-2015_10
- 特許番号
- US09150556B2
反応ノート
読み込み中…